{"generic":"Ceftazidime\/Avibactam","drugs":["Avycaz","Ceftazidime\/Avibactam"],"mono":{"0":{"id":"931363-s-0","title":"Generic Names","mono":"Ceftazidime\/Avibactam"},"1":{"id":"931363-s-1","title":"Dosing and Indications","sub":[{"id":"931363-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Complicated urinary tract infection, including pyelonephritis:<\/b> Ceftazidime 2 g\/avibactam 0.5 g infused over 2 hours IV every 8 hours for 7 to 14 days<\/li><li><b>Infectious disease of abdomen, Complicated, in combination with metronidazole:<\/b> Ceftazidime 2 g\/avibactam 0.5 g infused over 2 hours IV every 8 hours for 5 to 14 days. Give in combination with metronidazole.<\/li><\/ul>"},{"id":"931363-s-1-5","title":"Pediatric Dosing","mono":"Safety and efficacy are not established in pediatric patients."},{"id":"931363-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>Renal, CrCl 31 to 50 mL\/min (Cockcroft-Gault formula):<\/b> Ceftazidime 1 g\/avibactam 0.25 g infused over 2 hours IV every 8 hours<\/li><li><b>Renal, CrCl 16 to 30 mL\/min (Cockcroft-Gault formula):<\/b> Ceftazidime 0.75 g\/avibactam 0.19 g infused over 2 hours IV every 12 hours<\/li><li><b>Renal, CrCl 6 to 15 mL\/min (Cockcroft-Gault formula):<\/b> Ceftazidime 0.75 g\/avibactam 0.19 g infused over 2 hours IV every 24 hours<\/li><li><b>Renal, CrCl 5 mL\/min or less (Cockcroft-Gault formula):<\/b> Ceftazidime 0.75 g\/avibactam 0.19 g infused over 2 hours IV every 48 hours<\/li><li><b>Hemodialysis, CrCl 6 to 15 mL\/min (Cockcroft-Gault formula):<\/b> Ceftazidime 0.75 g\/avibactam 0.19 g infused over 2 hours IV every 24 hours given after hemodialysis on hemodialysis days<\/li><li><b>Hemodialysis, CrCl 5 mL\/min or less (Cockcroft-Gault formula):<\/b> Ceftazidime 0.75 g\/avibactam 0.19 g infused over 2 hours IV every 48 hours given after hemodialysis on hemodialysis days<\/li><\/ul>"},{"id":"931363-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Complicated urinary tract infection, including pyelonephritis<\/li><li>Infectious disease of abdomen, Complicated, in combination with metronidazole<\/li><\/ul>"}]},"3":{"id":"931363-s-3","title":"Contraindications\/Warnings","sub":[{"id":"931363-s-3-9","title":"Contraindications","mono":"Serious hypersensitivity to ceftazidime, avibactam, or other cephalosporin drugs <br\/>"},{"id":"931363-s-3-10","title":"Precautions","mono":"<ul><li>Gastrointestinal:<\/li><li>-- Clostridium difficile-associated diarrhea has been reported, severity can range from mild diarrhea to fatal colitis and some cases have occurred more than 2 months after administration; discontinue use and institute appropriate medical management if suspected or confirmed<\/li><li>Immunologic:<\/li><li>-- Serious and sometimes fatal anaphylactic reactions and serious skin reactions have been reported with beta-lactam antibacterial drug use; discontinue if allergic reaction occurs<\/li><li>-- Allergy to penicillin or other beta-lactam antibacterial drugs; use caution as cross sensitivity reaction my occur; discontinue if allergic reaction occurs<\/li><li>Neurologic:<\/li><li>--CNS reactions including seizures, nonconvulsive status epilepticus, encephalopathy, and coma have been reported, especially in patients with renal impairment; dosage adjustment may be necessary<\/li><li>Renal:<\/li><li>-- Renal impairment (CrCL of 50 mL\/min or less); decreased clinical response; increased risk for toxicity; monitoring recommended; dose adjustments required<\/li><li>Concomitant Use:<\/li><li>Concomitant use with probenecid is not recommended<\/li><li>Other:<\/li><li>-- Drug-resistant bacteria may develop when prescribed in the absence of bacterial infection<\/li><li>-- False positive reactions for glucose in the urine are possible with certain tests; glucose testing with enzymatic glucose oxidase reactions are recommended<\/li><li>-- Elderly patients (65 years or older) may be at increased risk for adverse effects; monitoring recommended; dose adjustments may be required depending on renal function<\/li><\/ul>"},{"id":"931363-s-3-11","title":"Pregnancy Category","mono":"B (FDA)<br\/>"},{"id":"931363-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"931363-s-4","title":"Drug Interactions","sub":{"1":{"id":"931363-s-4-14","title":"Major","mono":"<ul><li>Probenecid (probable)<\/li><li>Warfarin (probable)<\/li><\/ul>"},"2":{"id":"931363-s-4-15","title":"Moderate","mono":"<ul>Chloramphenicol (probable)<\/ul>"}}},"5":{"id":"931363-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Constipation (4% to 10%), Nausea (2% to 10%), Vomiting (14%)<\/li><li><b>Psychiatric:<\/b>Anxiety (5% to 10%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Clostridium difficile diarrhea<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Neurologic:<\/b>Asterixis, Encephalopathy, Excitability, Neuromuscular, Nonconvulsive status epilepticus, Seizure<\/li><li><b>Other:<\/b>Coma<\/li><\/ul>"},"6":{"id":"931363-s-6","title":"Drug Name Info","sub":{"0":{"id":"931363-s-6-17","title":"US Trade Names","mono":"Avycaz<br\/>"},"2":{"id":"931363-s-6-19","title":"Class","mono":"<ul><li>3rd Generation Cephalosporin<\/li><li>Antibiotic Combination<\/li><li>Beta-Lactamase Inhibitor<\/li><\/ul>"},"3":{"id":"931363-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"931363-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"931363-s-7","title":"Mechanism Of Action","mono":"Ceftazidime, a semisynthetic cephalosporin and avibactam, a beta-lactamase inhibitor exerts bacteriocidal activity when ceftazidime  binds to essential penicillin-binding proteins. Avibactam protects ceftazidime from degradation by inactivating beta lactamases allowing the ceftazidime concentration to exceed the minimum inhibitory concentration of susceptible microorganisms. Like other beta-lactam agents, ceftazidime has demonstrated time dependent antibacterial efficacy.<br\/>"},"8":{"id":"931363-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"931363-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding, ceftazidime: less than 10%; avibactam, 5.7% to 8.2%<\/li><li>Vd: ceftazidime: 17 to 18.1 L; avibactam: 22.2 to 23.2 L<\/li><\/ul>"},"2":{"id":"931363-s-8-25","title":"Metabolism","mono":"Avibactam, substrate of OAT1 and OAT3 transporters <br\/>"},"3":{"id":"931363-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: Avibactam: 0.2% unchanged<\/li><li>Renal: Ceftazidime: 80% to 90% unchanged; avibactam: 85% unchanged<\/li><li>Renal Clearance: Ceftazidime: 100 mL\/min; avibactam: 158 mL\/min<\/li><li>Dialyzable: Yes; 55% of avibacatm is removed<\/li><li>Total body clearance: Ceftazidime: 6.86 to 6.93 L\/hr; avibactam: 11.9 to 13.1 L\/hr<\/li><\/ul>"},"4":{"id":"931363-s-8-27","title":"Elimination Half Life","mono":"Ceftazidime: 2.76 to 3.27 hours; avibactam: 2.22 to 2.71 hours <br\/>"}}},"9":{"id":"931363-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>Reconstitute the powder for solution vial with 10 mL of sterile water for injection, NS, D5W, LR, or any combination of dextrose and sodium chloride, up to 2.5% dextrose and 0.45% sodium chloride.<\/li><li>Concentration of reconstituted solution is approximately ceftazidime 0.167 g\/avibactam 0.042 g per mL.<\/li><li>Dilute further with the same solution used to reconstitute the vial (except for sterile water for injection), to a total volume between 50 mL (ceftazidime 40 mg\/avibactam 10 mg per mL) to 250 mL (ceftazidime 8 mg\/avibactam 2 mg per mL).<\/li><li>Do not mix with other drugs as compatibility has not been established.<\/li><li>Administer within 12 hours if stored at room temperature. The diluted solution may be stored for up to 24 hours in the refrigerator and administered within 12 hours of subsequent storage at room temperature.<\/li><li>Infuse IV over 2 hours.<\/li><\/ul>"},"10":{"id":"931363-s-10","title":"Monitoring","mono":"<ul><li>CrCl, in patients with changing renal function; at least daily<\/li><li>Renal function, in elderly patients<\/li><\/ul>"},"11":{"id":"931363-s-11","title":"How Supplied","mono":"<b>Avycaz<\/b><br\/>Intravenous Powder for Solution: (Avibactam - Ceftazidime) 0.5 GM-2 GM<br\/>"},"12":{"id":"931363-s-12","title":"Toxicology","sub":[{"id":"931363-s-12-31","title":"Clinical Effects","mono":"<b>CEPHALOSPORINS<\/b><br\/>OVERDOSE: Acute ingestion of large doses of cephalosporins may result in nausea, vomiting, diarrhea, and abdominal pain. Seizures have developed after parenteral overdose. ADVERSE EFFECTS: COMMON: Hypersensitivity reactions, including anaphylaxis, may commonly occur with therapy; oral exposures are less likely to cause severe allergic reactions than parenteral exposures. Seizures have also been reported following therapeutic administration. Prolonged prothrombin times, thrombocytopenia, and coagulopathies associated with a qualitative platelet defect and aggregation abnormalities have been reported following IV cephalosporin therapy. Pseudocholelithiasis may follow intravenous administration of ceftriaxone. Several cases of fatal hemolytic reactions following intravenous ceftriaxone therapy have been reported in children with serious hematologic abnormalities.<br\/>"},{"id":"931363-s-12-32","title":"Treatment","mono":"<b>CEPHALOSPORINS <\/b><br\/><ul><li>Decontamination: Generally not indicated in patients with no underlying health problems. Activated charcoal may be necessary for patients with underlying renal insufficiency.<\/li><li>Support: Treatment is symptomatic and supportive.<\/li><li>Monitoring of patient: Monitor renal function, electrolytes, CBC including platelets.<\/li><li>Anaphylaxis: Mild to moderate allergic reactions may be treated with antihistamines with or without inhaled beta adrenergic agonists, corticosteroids or epinephrine. Diphenhydramine: ADULTS: 50 mg orally, IV, or IM initially, then 25 to 50 mg orally every 4 to 6 hours for 24 to 72 hours. CHILDREN: 1.25 mg\/kg orally, IV, or IM initially, then 5 mg\/kg\/day orally in 4 divided doses for 24 to 72 hours. Treatment of severe anaphylaxis also includes oxygen supplementation, aggressive airway management, epinephrine, ECG monitoring, and IV fluids.<\/li><li>Seizure: IV benzodiazepines, barbiturates<\/li><li>Blood coagulation disorder: Vitamin K, fresh frozen plasma<\/li><li>Intrathecal injection: Treat seizures with anticonvulsants (benzodiazepines, propofol, phenobarbital); endotracheal intubation and mechanical ventilation as needed. Keep the patient upright if possible. Immediately drain at least 20 mL CSF; drainage of up to 70 mL has been tolerated in adults. Follow with CSF exchange (remove serial 20 mL aliquots CSF and replace with equivalent volumes of warmed, preservative free normal saline or lactated ringers). For large overdoses, consult a neurosurgeon for placement of a ventricular catheter and begin ventriculolumbar perfusion (infuse warmed preservative free normal saline or lactated ringers through ventricular catheter, drain fluid from lumbar catheter; typical volumes 80 to 150 mL\/hr). Dexamethasone 4 mg intravenously every 6 hours to prevent arachnoiditis.<\/li><\/ul>"},{"id":"931363-s-12-33","title":"Range of Toxicity","mono":"<b>CEPHALOSPORINS<\/b><br\/>TOXICITY: Serious toxicity is unlikely following large oral doses of cephalosporins. Crystalluria and hematuria has been described in a 3-year-old boy who ingested 104 mg\/kg of cephalexin. THERAPEUTIC DOSE: Varies with agent. CEPHALEXIN: CHILDREN:  25 to 100 milligrams\/kilogram\/24 hours orally, up to a maximum of 4 grams\/day, divided every 6 hours. <br\/>"}]},"13":{"id":"931363-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to report symptoms of encephalopathy, myoclonus, seizures, or asterixis.<\/li><li>Instruct patient to report severe diarrhea and consult physician prior to taking antidiarrheal medicine.<\/li><li>Side effects may include vomiting, nausea, constipation, or anxiety.<\/li><\/ul>"}}}